Clinical trial · Observational
Glucose Monitoring During Chemotherapy
Pilot Study of Glucose Monitoring to Determine Rates of Hyperglycemia During Chemotherapy for Early Stage Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a research study to look at blood sugar changes during chemotherapy using a continuous blood sugar monitoring device. The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course. Each patch lasts for about 2-weeks. During chemotherapy visits, new patches will be placed and will be worn until the chemotherapy course is complete. Participants will be in this study for 6 months. Approximately 50 patients will be enrolled in this study.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Hyperglycemia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FreeStyle Libre Pro | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- FreeStyle Libre sensor cohort
- description
- Patients with early stage breast cancer will have their blood glucose levels monitored by the Freestyle libre pro sensor.
- interventionNames
- Device: FreeStyle Libre Pro
Primary outcomes (1)
- measure
- Prevalence of hyperglycemia
- timeFrame
- 24 weeks
- description
- assess the prevalence of HG, defined as the number of participants who have ≥1 glucose value of ≥140 mg/dL at any point during chemotherapy
Secondary outcomes (2)
- measure
- Prevalence of impaired glucose tolerance at baseline in nondiabetic patients.
- timeFrame
- Baseline
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years * History of stage I-III breast cancer * Patient scheduled to receive adjuvant or neoadjuvant chemotherapy * Signed informed consent Exclusion Criteria: * Current treatment with insulin * Current treatment with non-topical steroids, with the exception of steroid treatment as a supportive chemotherapy medication * Inability to provide informed consent
References
Publications (1)
- DERIVEDUlene SR, Wang S, Cook JR, McAuley F, Wooster ME, Faheem KF, Varoli A, McGuinness JE, Vasan N, Trivedi MS, Crew KD, Harden E, Law C, Hershman DL, Accordino MK. Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer. Breast Cancer Res Treat. 2025 Aug;212(3):511-519. doi: 10.1007/s10549-025-07745-z. Epub 2025 Jun 4. PMID 40468140